Welcome to our dedicated page for AdaptHealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AdaptHealth Corp. filings document the company’s healthcare-at-home operations, financial reporting and public-company governance. Its Form 8-K disclosures include quarterly and annual earnings releases, Regulation FD updates, financial guidance, business highlights and material events related to operating partnerships, asset dispositions and executive leadership changes.
The filing record also covers capital structure and financing matters, including credit agreements entered into by AdaptHealth LLC and related guarantees, collateral and borrowing commitments. AdaptHealth’s proxy materials describe board and executive compensation matters, while its securities disclosures identify common stock trading under AHCO on the Nasdaq Stock Market.
David S. Williams III, a director of AdaptHealth Corp. (AHCO), sold 8,200 shares on 08/22/2025 at a weighted average price of $9.73 per share. The filing shows the reported sales occurred in multiple transactions at prices ranging from $9.60 to $9.85, and the reporting person continues to beneficially own 50,045 shares following the transactions. The Form 4 was filed by one reporting person and signed by an attorney-in-fact, with a previously filed power of attorney incorporated by reference.
AdaptHealth Corp. 10-Q (Q2 2025) Reports net revenue of $800.4M for Q2 2025 and $1.578B for the six months ended June 30, 2025, relative to $806.0M and $1.598B a year earlier.
Operating income improved to $79.3M in Q2 driven by a $32.225M gain on sale of businesses; however, higher income tax expense ($35.9M in Q2) contributed to a Q2 net income of $15.8M and six-month net income of $9.7M, down vs. prior periods.
- Adjusted EBITDA declined to $155.5M in Q2 and to $283.5M for six months.
- Cash declined to $68.63M from $109.75M at year-end.
- Long-term debt decreased to $1.793B from $1.965B (repayments of $175.0M noted).
- Disposed two Wellness at Home businesses for gross proceeds of $120.835M and recognized related goodwill reductions.
AdaptHealth Corp. (AHCO) – Form 4 insider activity
Director Theodore B. Lundberg reported two acquisitions of AdaptHealth common stock on 06/26/2025:
- 21,346 shares acquired
- 7,864 shares acquired
Both transactions are recorded at $0, indicating they were equity grants or similar non-cash awards rather than open-market purchases. Following the transactions, Lundberg’s direct beneficial ownership rose to 859,756 shares. No dispositions, derivative securities, or 10b5-1 plan designations were disclosed, and the filing lists a Power of Attorney (Exhibit 24) supporting the submission.
The Form 4 contains no additional financial metrics or narrative commentary.
SEC Form 4 filed on 06/30/2025 shows AdaptHealth Corp. (AHCO) director Gregory Belinfanti acquired a total of 28,086 common shares on 06/26/2025 through two transactions recorded at $0.00 per share, indicating stock awards rather than open-market purchases. His direct holdings rose from an estimated 45,408 shares to 73,494 shares after the grants. No derivative securities were reported. While the amount is modest relative to AHCO’s float, the additional ownership slightly tightens insider–shareholder alignment and is typically viewed as a mildly positive governance signal.
AdaptHealth Corp. (AHCO) filed a Form 4 reporting an insider equity transaction by director Dale B. Wolf. On 26 June 2025, Wolf acquired 21,346 shares of common stock at a stated price of $0.00, a typical indicator of a stock award or equity grant rather than an open-market purchase. Following the award, his direct holdings rose to 96,235 shares, up roughly 28% from the prior 74,889-share position. In addition, Wolf continues to hold 14,000 shares indirectly through the Dale B. Wolf Generation Skipping Trust, for which he serves as investment manager.
No shares were sold and no derivative securities were exercised. The filing therefore represents a modest, non-cash increase in insider ownership and adds limited incremental dilution to AdaptHealth’s share count. While insider grants do not carry the same signaling power as open-market purchases, they can still improve alignment between the director and outside shareholders, especially when the shares are retained rather than immediately sold. Investors may view the award as a neutral-to-slightly-positive governance development; however, its dollar value appears immaterial relative to the company’s market capitalization and is unlikely to have a meaningful impact on valuation or liquidity.